Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.

Sussell, Jesse A; Roth, Joshua A; Meyer, Craig S; Fung, Anita; Hansen, Svenn A

Sussell, Jesse A; Roth, Joshua A; Meyer, Craig S; Fung, Anita; Hansen, Svenn A.

Affiliation

Sussell JA; Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA. sussellj@gene.com.
Roth JA; Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA.
Meyer CS; Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA.
Fung A; US Medical Affairs, Genentech, South San Francisco, CA, USA.
Hansen SA; F. Hoffmann-La Roche, Basel, Switzerland.

Adv Ther ; 39(3): 1375-1392, 2022 03.

Article in En | MEDLINE | ID: mdl-35094298

Subject(s)

Breast Neoplasms; Neoadjuvant Therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/pathology; Cost-Benefit Analysis; Female; Humans; Neoplasm Recurrence, Local/drug therapy; Receptor, ErbB-2/metabolism; Trastuzumab/therapeutic use

Key words

Cost-effectiveness; Neoadjuvant breast cancer; Pertuzumab; Trastuzumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Neoadjuvant Therapy Type of study: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2022 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google